Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.
Lucie ObericFrederic PeyradeMathieu PuyadeChristophe BonnetPeggy Dartigues-CuillèresBettina FabianiPhilippe RuminyHervé MaisonneuveJulie AbrahamCatherine ThieblemontPierre FeugierGilles Andre SallesFontanet BijouGian-Matteo PicaGandhi Laurent DamajCorinne HaiounRené-Olivier CasasnovasHassan FarhatRonan LE CallochAgathe Waultier-RascalouSandra MalakJerome PagetElodie GatHervé TillyFabrice JardinPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The addition of lenalidomide to R-miniCHOP does not improve OS. Rituximab delivered subcutaneously was safe in this population.